ZHONGZE Therapeutics is a clinical-stage biotech company dedicated to the research, development, and commercialization of innovative treatments for Psychiatric Disorders.

Our most advanced therapeutic compound, ZZ6398, effectively targets the core symptom domains of schizophrenia—positive symptoms, negative symptoms, and cognitive impairment—positioning it as a potential first-in-class (FIC) treatment. ZZ6398 has successfully obtained IND approvals in both China and the United States, with approved indications including schizophrenia and Major Depressive Disorder (MDD). Preclinical and clinical studies have shown that ZZ6398 exhibits excellent efficacy, safety, tolerability, and pharmacokinetic properties, aligning with the characteristics of a next-generation antipsychotic agent.  

ZHONGZE Therapeutics boasts a diverse pipeline of multi-mechanism therapies designed to meet the unmet clinical needs in the realm of psychiatric disorders.